Hepatic Oncology最新文献

Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma. 患者特征指导肝细胞癌的个性化治疗决策和预后。

IF 2

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-09-26 DOI: 10.1080/20450923.2026.2731868

Aaqid Syed, Mehmet Akce, Midhun Malla

{"title":"Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.","authors":"Aaqid Syed, Mehmet Akce, Midhun Malla","doi":"10.1080/20450923.2026.2731868","DOIUrl":"10.1080/20450923.2026.2731868","url":null,"abstract":"Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality and arises predominantly in cirrhotic livers, making prognosis and treatment response highly dependent on hepatic reserve and comorbidity. With multiple first-line immunotherapy and anti-VEGF based regimens, real-world decision making requires individualized selection integrating multiple patient related factors including liver function, bleeding risk, cardiovascular disease, and treatment feasibility among others. We reviewed pivotal first-line systemic therapy trials, complemented by key real-world cohorts evaluating outcomes in underrepresented populations. A targeted literature search was undertaken using PubMed/Medline and major oncology/hepatology meeting proceedings to identify prospective trials, guideline statements, and representative real-world studies focused on patient-level prognostic factors (Child-Pugh, ALBI), portal hypertension/varices, portal vein tumor thrombosis, cardiovascular risk, autoimmune disease, and transplant settings. We synthesize these data into a pragmatic framework to guide personalized regimen selection and improve prognostication in advanced HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2731868"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149065004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells. RTA - 408诱导p38依赖性细胞凋亡并抑制肝癌细胞活力。

IF 2

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-04-27 DOI: 10.1080/20450923.2026.2659967

Wei-Chieh Chen, Yoon Bin Chong, Hung-Pei Tsai, Tzu-Ting Tseng, Chen-Yu Wang, Shih-Hsun Kuo, Sheau-Fang Yang, Chun-Chieh Wu

{"title":"RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells.","authors":"Wei-Chieh Chen, Yoon Bin Chong, Hung-Pei Tsai, Tzu-Ting Tseng, Chen-Yu Wang, Shih-Hsun Kuo, Sheau-Fang Yang, Chun-Chieh Wu","doi":"10.1080/20450923.2026.2659967","DOIUrl":"10.1080/20450923.2026.2659967","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) remains difficult to treat, highlighting the need for new therapeutic strategies. RTA-408 (omaveloxolone), a synthetic oleanane triterpenoid and NRF2 pathway modulator, has reported anticancer activity, but its mechanisms in HCC are not fully understood.Materials and methods: HepG2 and PLC/PRF/5 (PP5) cells were treated with RTA-408 for 24 h. Cell viability, apoptosis, and signaling pathways were evaluated using MTT assay, Annexin V/7-AAD flow cytometry, and western blotting. The role of p38 signaling was examined using the p38 inhibitor SB203580.Results: RTA-408 reduced cell viability in a concentration-dependent manner and increased apoptosis in both cell lines. At 600 nM, apoptosis increased to approximately 18.43% in HepG2 cells and 24.71% in PP5 cells. RTA-408 increased p38 phosphorylation and NRF2 expression and was accompanied by LC3B and p62 accumulation and elevated cleaved caspase-3. Inhibition of p38 partially restored cell viability and reduced apoptosis.Conclusion: RTA-408 suppresses HCC cell survival through a p38-dependent stress response associated with NRF2 activation and LC3B/p62 accumulation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2659967"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study. 沙特三级保健中心肝细胞癌的特点：一项10年回顾性研究。

IF 2

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-09-17 DOI: 10.1080/20450923.2026.2731863

Rana Bokhary

{"title":"Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study.","authors":"Rana Bokhary","doi":"10.1080/20450923.2026.2731863","DOIUrl":"10.1080/20450923.2026.2731863","url":null,"abstract":"Aims: To evaluate the clinical and pathological characteristics of hepatocellular carcinoma (HCC) diagnosed at a tertiary care center in Saudi Arabia over a 10-year period.Materials and methods: This retrospective observational study included 44 patients diagnosed with HCC between January 2014 and December 2023. Demographic data, risk factors, tumor characteristics, and histopathological findings were extracted from medical records and pathology reports.Results: The cohort showed a male predominance (77.3%), with a mean age of 65.8 years. Nearly half of patients (45.5%) had negative viral hepatitis tests. Vascular invasion and portal vein thrombosis occurred in 25.0% and 22.7%, respectively. The trabecular growth pattern predominated, and many patients presented with advanced disease features and substantial tumor burden.Conclusion: HCC was frequently diagnosed at an advanced stage, with a substantial proportion of viral-negative cases. These exploratory findings are consistent with an evolving epidemiologic profile of HCC in Saudi Arabia but do not establish a causal relationship between metabolic factors and HCC. Despite its retrospective single-center design and small sample size, this study provides contemporary real-world data and highlights the need for improved surveillance, earlier detection, and larger multicenter studies.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2731863"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in liver transplantation for hepatic malignancies. 肝脏恶性肿瘤的肝移植研究进展。

IF 2

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-06-17 DOI: 10.1080/20450923.2026.2689312

Ingrid Woelfel, Shirley Lowmaster, Mariana Chavez-Villa, Sandra Arias, Channa Jayasekera, Michele Barnhill, Adyr Moss, Amit K Mathur, Nitin N Katariya

{"title":"Advances in liver transplantation for hepatic malignancies.","authors":"Ingrid Woelfel, Shirley Lowmaster, Mariana Chavez-Villa, Sandra Arias, Channa Jayasekera, Michele Barnhill, Adyr Moss, Amit K Mathur, Nitin N Katariya","doi":"10.1080/20450923.2026.2689312","DOIUrl":"10.1080/20450923.2026.2689312","url":null,"abstract":"Transplant Oncology is an evolving field. While liver transplantation was once contraindicated in patients with cancer, the safety and survival benefit of utilizing transplantation as a curative-intent treatment for primary and metastatic hepatic malignancies has been demonstrated. Currently, liver transplantation is offered to selected patients with hepatocellular carcinoma, perihilar and intrahepatic cholangiocarcinoma, colorectal cancer with isolated liver metastases, and neuroendocrine tumors with isolated liver metastases. We will cover the current inclusion and exclusion criteria and clinical and pathologic factors of each oncologic indication, and future directions in liver transplant oncology. Successful oncologic outcomes for liver transplantation hinge on careful selection of patients. The evolving role of immunotherapy and targeted tumor therapies have allowed for previously transplant-ineligible patients to be considered for curative-intent transplantation, rather than palliative-intent care. Increasing our knowledge through coordinated multi-institutional studies of each disease process with liver transplantation will be imperative to continue to safely broaden the indications and offer hope to these complex groups of patients. Reframing recipients with oncologic indications for transplant should occur carefully and with attention to rigorous analysis of clinical outcomes. The objective of this article is to situate the evolving treatments for hepatic malignancies within the expanding scope of transplant oncology.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2689312"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization. 美国不可切除HCC患者栓塞治疗的治疗模式和结果。

IF 2

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-10-19 DOI: 10.1080/20450923.2026.2736861

Kirema Garcia-Reyes, William H Wang, Mufiza Farid-Kapadia, Nehemiah Kebede, Dex L Underwood, Ling Cai, Heide A Stirnadel-Farrant, Cindy Wang, Neehar D Parikh

{"title":"Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization.","authors":"Kirema Garcia-Reyes, William H Wang, Mufiza Farid-Kapadia, Nehemiah Kebede, Dex L Underwood, Ling Cai, Heide A Stirnadel-Farrant, Cindy Wang, Neehar D Parikh","doi":"10.1080/20450923.2026.2736861","DOIUrl":"10.1080/20450923.2026.2736861","url":null,"abstract":"Aims: To describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.Materials & methods: This retrospective observational study used Optum's de-identified Market Clarity Data. US adults with HCC treated with embolization between July 2016-September 2022 were followed from first embolization following diagnosis until death and end of enrollment or study period.Results: Of 1,458 patients, 41.9%, 33.5%, and 24.6% received transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and transarterial embolization (TAE), respectively, as initial embolization therapy; TARE use increased over time. Most were male (74.6%), white (66.5%), with a median age at index of 65.0 years, and 63.1% required ≥1 subsequent treatment (median treatment pattern follow-up: 16.3 months). Median (95% CI) time to first follow-up treatment or death was 5.9 (5.5-6.4) months. Compared with TARE, risk of death was lower with TACE (HR [95% CI] 0.82 [0.69-0.97]; P = 0.0242], non-significant in missingness sensitivity analysis) and higher with TAE (HR [95% CI] 1.25 [1.05-1.49]; P = 0.0135]).Conclusion: TARE was the most common initial embolization therapy and its use increased over time. Time to first follow-up treatment or death was relatively short. Future studies are needed to identify optimal treatment approaches.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2736861"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Racial and ethnic survival disparities in primary liver cancer in the United States: a National Cancer Database propensity score-matched study. 美国原发性肝癌的种族和民族生存差异：一项国家癌症数据库倾向评分匹配研究

IF 2

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-09-12 DOI: 10.1080/20450923.2026.2731867

Muhammet Ozer, Suleyman Y Goksu, Amy L Jones, Timothy J Brown, Nina Sanford, Nilesh Verma, Salwan Al Mutar, David Hsieh, Syed M Kazmi

{"title":"Racial and ethnic survival disparities in primary liver cancer in the United States: a National Cancer Database propensity score-matched study.","authors":"Muhammet Ozer, Suleyman Y Goksu, Amy L Jones, Timothy J Brown, Nina Sanford, Nilesh Verma, Salwan Al Mutar, David Hsieh, Syed M Kazmi","doi":"10.1080/20450923.2026.2731867","DOIUrl":"10.1080/20450923.2026.2731867","url":null,"abstract":"Introduction: Primary liver cancer is a leading cause of cancer mortality worldwide. We evaluated whether racial and ethnic survival disparities among US patients with primary liver cancer persist after adjustment for clinical, treatment, socioeconomic, and access-related factors.Methods: We performed a retrospective cohort study using the National Cancer Database. Race was analyzed as White versus Black, and race/ethnicity groups were defined as non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic of any race. Overall survival (OS) was assessed using Kaplan-Meier analysis, log-rank testing, multivariable Cox regression, and 1:1 propensity score matching for the White-versus-Black comparison.Results: Among 122,049 patients diagnosed between 2004 and 2016, Black patients more often presented with advanced disease and were less likely to receive surgery, chemotherapy, or radiotherapy. In the unmatched analysis, White patients had better OS. After matching, race was not an independent predictor of survival (HR 0.98, p = 0.11). Hispanic ethnicity remained associated with improved survival compared with NHW and NHB patients (HR 1.32 and 1.29; both p < 0.001).Conclusion: The unadjusted survival difference between White and Black patients was attenuated after adjustment for clinical, treatment, socioeconomic, and access-related factors. Hispanic ethnicity remained associated with improved survival in secondary analyses, warranting further investigation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2731867"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma. 定性研究以了解晚期和/或转移性肝细胞癌患者的经历。

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-10-23 DOI: 10.1080/20450923.2025.2567741

Sally Lanar, Asma Kefsi, Maria Armaou, Fallon Jones-Lemmons, Marie de La Cruz, Kelly Lipman, Benoit Arnould, Cécile Gousset

{"title":"Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma.","authors":"Sally Lanar, Asma Kefsi, Maria Armaou, Fallon Jones-Lemmons, Marie de La Cruz, Kelly Lipman, Benoit Arnould, Cécile Gousset","doi":"10.1080/20450923.2025.2567741","DOIUrl":"10.1080/20450923.2025.2567741","url":null,"abstract":"Aim: The present study aimed to explore the patient experience in advanced and/or metastatic hepatocellular carcinoma (HCC).Materials & methods: A multi-phase research design was followed that included a targeted literature review (TLR), interviews with clinicians, and interviews with patients. Patient interviews were analyzed using an iterative, thematic analysis approach. An assessment of the conceptual saturation of all spontaneously patient-reported signs and symptoms was conducted.Results: Ten patient-centric qualitative studies were identified in the TLR. Five United States (US) clinicians and 15 US patients participated in semi-structured interviews, conducted via video conferencing, lasting approximately 60 minutes each. The five most commonly reported symptoms were fatigue, weight loss, weakness, reduction in appetite, and sleep disturbance. Furthermore, HCC impacted all aspects of patients' lives, including physical functioning, social and family functioning, emotional functioning, physical activities, and activities of daily living. The concepts were mostly similar across the different data sources. A patient-centric conceptual model was developed based on the TLR and patient interviews.Conclusion: The study provides an in-depth description of signs/symptoms and impacts in advanced and/or metastatic HCC that can support the identification of suitable patient-reported outcome measures. Separate investigation is needed to distinguish between disease impacts and treatment impacts.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2567741"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12562793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145349097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of hepatocellular carcinoma prior to liver transplantation: latest developments. 肝移植前肝细胞癌的处理：最新进展。

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-08-23 DOI: 10.1080/20450923.2025.2549676

Antoine Robert, Thomas M Hunold, Neehar D Parikh

{"title":"Management of hepatocellular carcinoma prior to liver transplantation: latest developments.","authors":"Antoine Robert, Thomas M Hunold, Neehar D Parikh","doi":"10.1080/20450923.2025.2549676","DOIUrl":"10.1080/20450923.2025.2549676","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts transplant to patients with early HCC, and priority for transplant is granted after 6 months on the waitlist, thus patients often require therapies for cancer control while awaiting liver transplantation. The most commonly applied therapies for HCC in patients awaiting liver transplantation are locoregional therapies, including ablative, radiation, and arterial based therapies. Using these therapies patient can be effectively bridged or downstaged to liver transplantation, however there are risks of progressive liver decompensation with locoregional therapies in patients with portal hypertension. There are emerging data for the use of immune checkpoint inhibitor-based immunotherapies in the treatment of HCC. While there has been concern for rejection with the administration of immunotherapy prior to liver transplantation, early data suggest that the risk can be minimized with sufficient washout time prior to liver transplantation. Herein we aim to review management strategies for patients with HCC awaiting liver transplantation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2549676"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update. 肝动脉输注化疗在不可切除的肝细胞癌患者中的应用：3年生存更新。

IF 1.2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-06-17 DOI: 10.1080/20450923.2025.2516994

Shiguang Chen, Wenchang Yu, Xiaolong Wang, Weifu Liu

引用次数: 0

Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. 免疫检查点抑制剂治疗肝癌患者的临床管理。

IF 2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-10-30 DOI: 10.1080/20450923.2025.2578079

Johnny C W Yau, Landon L Chan, Stephen L Chan

{"title":"Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.","authors":"Johnny C W Yau, Landon L Chan, Stephen L Chan","doi":"10.1080/20450923.2025.2578079","DOIUrl":"10.1080/20450923.2025.2578079","url":null,"abstract":"The treatment paradigm of hepatocellular carcinoma (HCC) has evolved with the emergence of immune checkpoint inhibitors (ICIs). Two ICI-based regimens have gained regulatory approval worldwide in unresectable HCC as first line treatment based on the IMBrave150 and HIMALAYA trial. Other regimens such as camrelizumab-rivoceranib and ipilimumab-nivolumab also demonstrated improvement in overall survival as compared to multi-targeted agents in recent phase III clinical trials. With the growing amount of evidence, it is imperative for clinicians to decide the most suitable ICI therapy for each patient based on their disease status and tolerability. Furthermore, ICI in combination with locoregional treatment such as transarterial chemoembolization (TACE) has been shown to prolong the progression-free survival as compared to TACE alone. In early-stage HCC, the role of ICI has been studied in both the adjuvant and neoadjuvant setting. In this narrative review, we will highlight the major advancement of ICI in different stages of HCC and their implication in real world practice. The unmet need in the special population of liver cancer patients and the management of immune-related hepatitis will also be addressed.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2578079"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12578309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0